#Endo international plc founder full#
#Endo international plc founder free#

until it was acquired by Endo International plc. Adams served as chief executive officer and president of Auxilium Pharmaceuticals Inc. From December 2011 until January 2015, Mr. Adams served as chief executive officer and a member of the board of directors of Pozen, Inc.

Prior to that, from May 2015 to January 2016, Mr. from February 2016 to January 2019 and served as a member of the board of directors from February 2016 to April 2019. Adams served as chief executive officer of Aralez Pharmaceuticals, after the merger between Pozen, Inc. Adams has served as chairman of the board of directors of Akebia Therapeutics, Inc. Adams has also served as chairman of the board of directors of Impel NeuroPharma, Inc., and in May 2020 he took on the additional role of chief executive officer.

Adams has served as the Chairman of the AcelRx board of directors since February 2013. Simply Wall St has no position in any stocks mentioned.Mr.

Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly.

#Endo international plc founder full#

This may not be consistent with full year annual report figures. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated.

#Endo international plc founder free#

Luckily, you can check this free report showing analyst forecasts for its future. If you are like me, you may want to think about whether this company will grow or shrink. Be aware that Endo International is showing 3 warning signs in our investment analysis, and 1 of those is a bit concerning. But to truly gain insight, we need to consider other information, too. I find it very interesting to look at who exactly owns a company. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. The general public, who are usually individual investors, hold a 17% stake in Endo International. You can click here to see if those insiders have been buying or selling. Many investors in smaller companies prefer to see the board more heavily invested. It seems the board members have no more than US$998k worth of shares in the US$123m company. Our information suggests that Endo International plc insiders own under 1% of the company. This can be negative in some circumstances. However, high insider ownership can also give immense power to a small group within the company. Insider ownership is positive when it signals leadership are thinking like the true owners of the company.

Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Our data reflects individual insiders, capturing board members at the very least. The definition of company insiders can be subjective and does vary between jurisdictions.